Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Ovarian Cancer treatment details. Chemotherapy. Université Paris Descartes, Paris, France



Survival: 13.3 months
   
Toxicity Grade: 5
   
Treatments: Chemotherapy
   
Drugs:
Country: France
   
City/State/Province: Paris
   
Hospital: Université Paris Descartes
   
Journal: Link
   
Date: 5/2014

Description:
Patients:
This phase 3 study involved ovarian cancer patients who had received prior platinum-based chemotherapy and were divided into two separate treatment groups. Group A consisted of 182 patients with a median age of 61 years. Group B had 179 patients with a median age of 62 years.

Treatment:
Patients in group A received chemotherapy with pegylated liposomal doxorubicin, paclitaxel, or topotecan.

Patients in group B received biologic therapy with bevacizumab and chemotherapy with pegylated liposomal doxorubicin, paclitaxel, or topotecan.

Toxicities:
Treatment-related deaths due to infection with neutropenia, heart failure, septic shock, peritonitis (inflammation in the abdomen), and GI bleeding were reported for group A. Grade 3-4 fatigue, vomiting, and abdominal pain were also reported.

Treatment-related deaths due to infection with neutropenia, GI bleeding, GI perforation, heart attack, and shock were reported for group B. Grade 34 nerve toxicity, hand-foot skin reaction, and diarrhea were also reported.

Results:
The median overall survival for groups A and B was 13.3 and 16.6 months, respectively.

Support:
This study was supported by Hoffmann-La Roche.

Correspondence: Dr. Eric Pujade-Lauraine; email: epujade@arcagy.org

E-mail to a Friend Email Physician More Information